1.41

0.00% 0.00

Atossa Therapeutics Inc (ATOS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Atossa Therapeutics Inc stock is traded at $1.41, with a volume of 173.69K. It is up +0.00% in the last 24 hours and down -4.08% over the past month. Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Previous Close:

$1.41

Open:

$1.42

24h Volume:

173.69K

Relative Volume:

0.35

Market Cap:

$177.32M

Revenue:

Net Income/Loss:

$-29.69M

P/E Ratio:

-5.64

EPS:

-0.25

Net Cash Flow:

$-18.64M

1W Performance:

-1.40%

1M Performance:

-4.08%

6M Performance:

-15.06%

1Y Performance:

+101.43%

1-Day Range:

$1.38

$1.42

1-Week Range:

$1.35

$1.44

52-Week Range:

$0.62

$2.31

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name

Atossa Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

206.588.0256

Address

10202 5TH AVENUE NE, SEATTLE, WA

Employee

Twitter

@atossainc

Next Earnings Date

2024-11-11

Latest SEC Filings

ATOS's Discussions on Twitter

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-18	Initiated	Maxim Group	Buy

Atossa Therapeutics Inc Stock (ATOS) Latest News

08:50 AM

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development - The Manila Times

08:50 AM

01:54 AM

Vanguard Group Inc's Strategic Acquisition of Atossa Therapeutics Inc Shares - GuruFocus.com

01:54 AM

Nov 04, 2024

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: - The Manila Times

Nov 04, 2024

Atossa Therapeutics (NASDAQ:ATOS) Receives “Buy” Rating from HC Wainwright - Defense World

Nov 04, 2024

Oct 31, 2024

Atossa Therapeutics' (ATOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 31, 2024

ATOSAtossa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 31, 2024

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer - ForexTV.com

Oct 31, 2024

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer - The Manila Times

Oct 31, 2024

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s - The Bakersfield Californian

Oct 31, 2024

Oct 28, 2024

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance

Oct 28, 2024

Oct 25, 2024

Atossa Therapeutics (NASDAQ:ATOS) Upgraded to "Hold" at StockNews.com - MarketBeat

Oct 25, 2024

Oct 23, 2024

Atossa Therapeutics (NASDAQ:ATOS) Shares Cross Above 200 Day Moving AverageHere's Why - MarketBeat

Oct 23, 2024

Oct 21, 2024

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer - The Manila Times

Oct 21, 2024

Oct 14, 2024

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit - ForexTV.com

Oct 14, 2024

Atossa Therapeutics To Present At The 2024 Maxim Healthcare Virtual Summit - Barchart

Oct 14, 2024